Repligen Corporation Investor Presentation — May 2020

Document content

May 2020Investor PresentationSafe Harbor

This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of

Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

amended. These statements are subject to risks and uncertainties which may cause our plans to change or actual

results to differ materially from those anticipated. In particular, unforeseen events outside of our control may

adversely impact future results. Additional information concerning these factors is discussed in our reports filed

with the Securities and Exchange Commission including recent Form 8 -Ks, our most recent Annual Report on Form

10K and our most recent Quarterly Reports on Form 10Q. The forward looking statements in this presentation

reflect management’s current views and may become obsolete as a result of new information, future events or

otherwise. We may not update such forward looking statements to reflect a change of events or circumstances

that occur after the date hereof, except as required by law. The industry and market data contained in this

presentation are based on management’s own estimates, independent publications, government publications,

reports by market research firms or other published independent sources, and, in each case, are believed by

management to be reasonable estimates. Although we believe these sources are reliable, we have not

independently verified the information.

Advancing innovation as a trusted partner in the production

Bioprocessing innovator with

diversified portfolio

Enabling efficient, single

high productivity manufacturing

Differentiated, disruptive products

with high brand recognition

Accelerating demand from

Supported by a robust and

expanding global biologics market>760

from ~550 at YE 2018REVENUE SPLITS

FY 2019Market Drivers, Addressable MarketsStrong End Markets for Bioprocessing

1. Antibodies to Watch in 2019 MAbs . 2019 Feb/Mar 11(2)219 -238 PubMed link , FDA.gov

2. Alliance for Regenerative Medicine Q3 2019 report ARM report , FDA.gov; Includes gene therapy and gene -modified cell therapy

3. SDI Bioprocessing Market Analysis and Perspectives Sept. 2018Monoclonal

Preview truncated — download the full document for the complete content.